46岁药企董事长，因涉嫌刑事犯罪被批捕

Core Viewpoint - The recent arrest of the chairman and president of Beida Pharmaceutical, Xu Xiren, due to criminal allegations has raised concerns about the company's leadership stability and operational continuity [1][4]. Group 1: Company Leadership and Management - Xu Xiren has been arrested by the Chongqing Jiangbei District People's Procuratorate, which has led to the delegation of his responsibilities to other board members [1][4]. - The company’s control remains unchanged, and the board of directors is functioning normally despite the leadership changes [4]. - Xu Xiren became the actual controller of Beida Pharmaceutical in early 2025, but was detained just 10 months after taking control [4]. Group 2: Financial Performance - In Q3, Beida Pharmaceutical reported a revenue of 274 million yuan, a year-on-year decrease of 47.95%, and a net profit attributable to shareholders of 35.6867 million yuan, down 18.04% [4]. - For the first three quarters, the company achieved a revenue of 1.231 billion yuan, a year-on-year decline of 19.76%, while the net profit attributable to shareholders increased by 4.31% to 136 million yuan [4]. Group 3: Company Background and Ownership Changes - Beida Pharmaceutical, originally established in 1965, was listed on the Shenzhen Stock Exchange in 1997 and became part of the New Fangzheng Group under China Ping An in 2022 [5]. - The company underwent two rounds of actual controller changes, with Beijing University no longer being the actual controller as of December 2024 [5]. - The current market capitalization of Beida Pharmaceutical is approximately 3.98 billion yuan, with its stock price rising recently due to the strengthening of the anti-influenza concept in the secondary market [5].